Star Therapeutics News and Activities

Star Therapeutics is owned by InvoX Pharma. InvoX Pharma has a direct presence in 2 countries.

They are in:

• Pharmaceuticals50%
• Biotechnology50%

Acquisition, funding and merger involving InvoX Pharma.

• Incyte has announced the acquisition of Star Therapeutics  (posted on June 9 2026).
• Star Therapeutics has just announced a $125 Million fundraising (posted on October 2 2025).

View the org chart displaying its 20 main executives

Most searched biographies at Star Therapeutics

• Adam Rosenthal, Chief Executive Officer
• Jason Hafler, Director
• Carl Gordon, Director

Popular executive movements at Star Therapeutics

• Meli Paraganlija who was Senior Manager, Clinical Trial, becomes Associate Director, Clinical Trial  (posted on April 3 2026).
• Annie Michalek, who was Clinical Trial Manager, is promoted to Senior Manager, Clinical Trial  (posted on April 3 2026).

Create your alert
to follow the executive moves at Star Therapeutics.

InvoX Pharma has 2,432 competitors including Vertex Pharmaceuticals (United States (USA)), Lonza (Switzerland) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Crystalys Therapeutic has just announced a $130 Million fundraising (posted on July 23 2026).
• Ipsen has acquired Memo Therapeutics (posted on July 22 2026).
• AdvanCell has just announced a $315 Million fundraising (posted on July 21 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Star Therapeutics

• Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio | Incyte
• Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders | Incyte
• Star Therapeutics details early data for blood disorder shot, weighs IPO potential
• Star raises another $125M for its blood disease drug
• Star gets $125M Series D as it begins Phase 3 in bleeding disorders
• Von Willebrand disease: Star Therapeutics, Chugai and Band Therapeutics are breaking new ground
• Backed by $100M, Star Therapeutics sets out to find constellations of rare disease - STAR Therapeutics
• News - STAR Therapeutics
• View more press releases Close

Social media about Star Therapeutics

• Star Therapeutics on Wikipedia, Google News & Yahoo Finance
• Star Therapeutics on LinkedIn, X (Twitter) & YouTube